Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer

Chest

Volumn 134, Issue 3, 2008, Pages 582-588

  Sin, Don D ^a   Man, S F Paul ^a   McWilliams, Annette ^b   Lam, Stephen ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b NONE

Author keywords

Biomarker; Bronchial dysplasia; Surfactant protein D

Indexed keywords

BUDESONIDE; C REACTIVE PROTEIN; GLUTATHIONE DISULFIDE; PLACEBO; SURFACTANT PROTEIN D;

ADULT; ARTICLE; BRONCHOSCOPY; BRONCHUS BIOPSY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; DISEASE COURSE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG DYSPLASIA; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEAT PROCEDURE; SMOKING;

EID: 51649086084     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0600     Document Type: Article

References (33)

1. American Cancer Society. Cancer facts and figures 2008. Atlanta, GA: American Cancer Society, 2008
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355:479-485
3. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol 2003; 4:45-55
4. Malhotra S, Lam S, Man SF, et al. The relationship between stage 1 and 2 non-small cell lung cancer and lung function in men and women. BMC Pulm Med 2006; 6:2
5. Papi A, Casoni G, Caramori G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004; 59:679-681
6. MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117(suppl):303S-317S
7. Paz-Elizur T, Krupsky M, Elinger D, et al. Repair of the oxidative DNA damage 8-oxoguanine as a biomarker for lung cancer risk. Cancer Biomark 2005; 1:201-205
8. Lin Z, Thomas NJ, Bibikova M, et al. DNA methylation markers of surfactant proteins in lung cancer. Int J Oncol 2007; 31:181-191
9. Sin DD, Leung R, Gan WQ, et al. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007; 7:13
10. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers: a different disease. Nat Rev Cancer 2007; 7:778-790
11. Wert SE, Yoshida M, LeVine AM, et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci U S A 2000; 97:5972-5977
12. Starosta V, Griese M. Oxidative damage to surfactant protein D in pulmonary diseases. Free Radic Res 2006; 40:419-425
13. Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004; 10:6502-6511
14. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18:1059-1068
15. Lam S, Leriche JC, Kijek K, et al. Effect of bronchial lavage volume on cellular and protein recovery. Chest 1985; 88:856-859
16. Lam S, leRiche JC, Zheng Y, et al. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 1999; 91:691-696
17. American Thoracic Society. Standardization of spirometry: 1987 update; statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136:1285-1298
18. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664
19. Richie JP Jr, Skowronski L, Abraham P, et al. Blood glutathione concentrations in a large-scale human study. Clin Chem 1996; 42:64-70
20. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60:532-538
21. Sin DD, Man SF, McWilliams A, et al. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 2006; 173:535-539
22. Mori K, Kurihara N, Hayashida S, et al. The intrauterine expression of surfactant protein D in the terminal airways of human fetuses compared with surfactant protein A. Eur J Pediatr 2002; 161:431-434
23. Sorensen GL, Hjelmborg JB, Kyvik KO, et al. Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol 2006; 290:L1010-L1017
24. Kierstein S, Poulain FR, Cao Y, et al. Susceptibility to ozone-induced airway inflammation is associated with decreased levels of surfactant protein D. Respir Res 2006; 7:85
25. Casey J, Kaplan J, Atochina-Vasserman EN, et al. Alveolar surfactant protein D content modulates bleomycin-induced lung injury. Am J Respir Crit Care Med 2005; 172:869-877
26. Crouch EC. Surfactant protein-D and pulmonary host defense. Respir Res 2000; 1:93-108
27. Sadowska AM, van Overveld FJ, Gorecka D, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med 2005; 99:241-249
28. Sugiura H, Ichinose M, Yamagata S, et al. Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD. Thorax 2003; 58:299-305
29. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997; 57:5489-5492
30. Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:712-719
31. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60:992-997
32. Breuer RH, Pasic A, Smit EF, et al. The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res 2005; 11:537-543
33. Zhang F, Pao W, Umphress SM, et al. Serum levels of surfactant protein D are increased in mice with lung tumors. Cancer Res 2003; 63:5889-5894